Announcement

Collapse
No announcement yet.

Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors

Collapse
X
  • Filter
  • Time
  • Show
Clear All
new posts

  • Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors

    Front Cell Infect Microbiol. 2019 Mar 26;9:67. doi: 10.3389/fcimb.2019.00067. eCollection 2019.
    Virtual Screen for Repurposing of Drugs for Candidate Influenza a M2 Ion-Channel Inhibitors.

    Radosevic D1, Sencanski M1, Perovic V1, Veljkovic N1, Prljic J1, Veljkovic V2, Mantlo E3, Bukreyeva N3, Paessler S3,4, Glisic S1.
    Author information

    Abstract

    Influenza A virus (IAV) matrix protein 2 (M2), an ion channel, is crucial for virus infection, and therefore, an important anti-influenza drug target. Adamantanes, also known as M2 channel blockers, are one of the two classes of Food and Drug Administration-approved anti-influenza drugs, although their use was discontinued due to prevalent drug resistance. Fast emergence of resistance to current anti-influenza drugs have raised an urgent need for developing new anti-influenza drugs against resistant forms of circulating viruses. Here we propose a simple theoretical criterion for fast virtual screening of molecular libraries for candidate anti-influenza ion channel inhibitors both for wild type and adamantane-resistant influenza A viruses. After in silico screening of drug space using the EIIP/AQVN filter and further filtering of drugs by ligand based virtual screening and molecular docking we propose the best candidate drugs as potential dual inhibitors of wild type and adamantane-resistant influenza A viruses. Finally, guanethidine, the best ranked drug selected from ligand-based virtual screening, was experimentally tested. The experimental results show measurable anti-influenza activity of guanethidine in cell culture.


    KEYWORDS:

    IAV matrix protein 2; drug repurposing; drug resistance; influenza A; virtual screening

    PMID: 30972303 PMCID: PMC6443897 DOI: 10.3389/fcimb.2019.00067
    Free full text
Working...
X